Tuesday, November 02, 2021 1:50:19 PM
A stunning new study that was conducted by researchers from the Mayo Clinic in Rochester, Minnesota has concluded that the Johnson & Johnson Covid vaccine increases the risk of developing a rare and deadly blood clotting condition in the brain.
The study, which was published on Monday in the Journal of the American Medical Association (JAMA), found that recipients of the one-shot J&J vaccine are 3.5 times more likely (8.65 per 100,000) to develop cerebral venous sinus thrombosis (CVST) when compared to the general population (2.34 per 100,000).
“The overall age- and sex-adjusted CVST incidence [within the general population before the Covid-19 outbreak] was 2.34 per 100?000 person-years. Age-adjusted CVST rates for female and male individuals were 2.46 per 100?000 PY and 2.34 per 100?000 PY, respectively.
The overall incidence rate of post–Ad26.COV2.S [Johnson & Johnson] vaccination CVST was 8.65 per 100?000 PY at 15 days, 5.02 per 100?000 PY at 30 days, and 1.73 per 100?000 PY at 92 days.”
Researchers compared public health data from before the Covid-19 outbreak to reports of verified cases of CVST that were recorded in the CDC’s Vaccine Adverse Events Reporting System (VAERS).
The study also found that women were most at risk after taking the J&J jab, checking in at a whopping 5.1 times more likely to develop the deadly condition.
They accounted for over 70% of the new cases of CVST that were directly linked to J&J in VAERS.
The postvaccination CVST rate among females was 5.1-fold higher compared with the pre-COVID-19 pandemic rate (13.01 vs 2.53 per 100?000 PY; P?<?.001) (Table 2).
When researchers factored in the ages of the women, the results were even more shocking. Women who were 40-49 years old had the highest risk of any subset at 29.5 per 100,000, which is an astounding 11.5 times higher risk of developing the condition than the general population.
Women in the 30-39 age range were right behind with a rate of 26.5 per 100,000.
This risk was highest among women aged 40 to 49 years (29.50 per 100?000 PY, followed by women aged 30 to 39 years (26.50 per 100?000 PY; 10.65-54.63 per 100?000 PY).
In their population-based analysis, researchers compared the total number of diagnosed cases of CVST in Olmsted County, Minnesota from 2001-2015 with relatable VAERS data from February 28th, 2021 (J&J vaccine’s FDA EUA approval date) through May 7th, 2021.
During the 14 year base period, they found that just 39 Olmsted residents had developed the life-threatening condition, which equated to a rate of 2.53 per 100,000 once the researchers adjusted for time and population.
On the other hand, in just over 2 and a half months, 46 reports of J&J-linked CVST had already been logged into VAERS – 8 of which were not included in the study due to lack of documentation. In total, researchers were able to fully verify 38 cases, which they determined is a significantly higher rate of 8.65 per 100,000.
Although the study showed that J&J vaccine recipients have a 3.5 times higher overall risk of developing brain clotting, the rate could easily be much higher. Not only did researchers exclude 8 of the cases, but, as The Gateway Pundit has previously reported, VAERS data could be undercounted by as much as a factor of 100.
The J&J vaccine is the least popular of the three Covid jabs that are available in the US. During the 2 and a half months that were analyzed by researchers, there had been just over 8.7 million doses that were administered to Americans.
The concerns over blood clotting grew so loud that the FDA infamously paused its EUA for the J&J shot in April after six women had developed CVST shortly after inoculation – Just ten days after, on April 23, usage of the vaccine was resumed after a warning label for women about the blood clots was added to the product.
Despite all of the concerns, the J&J jab is still available in the US, and as of now, there have been over 15.6 million doses that have been administered since the beginning of the year when it was granted its current Emergency Use Approval (EUA).
This begs just one question, when will the public health ‘experts’ start following the ‘science?’ (Well, never – it’s all about power – but at least its getting much more difficult for them to deny reality and keep gaslighting the public by telling them this is the “pandemic of the unvaccinated”)
More and more data has come out that shows how these rushed vaccines have been a direct cause of multiple deadly, rare conditions in otherwise healthy individuals. What’s even more troubling is how our public health dictatorship is systematically covering up the evidence. All three of the currently ‘approved’ vaccines provide almost no protection against the virus, and the little that is provided will disappear over a few months, which requires the fully vaccinated individual to require an even more rushed booster jab.
It’s no wonder the CDC had to change its definition of “vaccine” and “vaccination” from something that provides “immunity,” to “a preparation that is used to stimulate the body’s immune response against diseases.”
In fact, the vaccine has done such a poor job at what it is intended to do that fully vaccinated people in places like the UK and Israel account for the vast majority of new cases, as well as an overwhelming percentage of recent deaths.
Keep in mind, for the vast majority of people, Covid-19 is not a deadly virus, and – if symptoms even manifest at all – equates to something along the lines of the seasonal flu. Over 99.5% (closer to 99.9%) of individuals who catch the virus will recover, and once they do, natural immunity provides better and longer-lasting protection than any of the lab-created vaccinations.
Recent JNJ News
- Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) • Business Wire • 04/22/2024 08:30:00 PM
- Paramount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and More • IH Market News • 04/19/2024 11:31:22 AM
- US Index Futures See Gains, Oil Prices Dip • IH Market News • 04/17/2024 10:59:02 AM
- U.S. Stocks Finish Lackluster Session Narrowly Mixed • IH Market News • 04/16/2024 08:33:00 PM
- CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 02:46:00 PM
- J&J’s Q1 2024 sales rise 2.3% to $21.4 billion • IH Market News • 04/16/2024 01:52:44 PM
- Dow Looks To Snap Six-Day Losing Streak As UnitedHealth Surges • IH Market News • 04/16/2024 01:09:47 PM
- U.S. Index Futures Signal Mixed Trading, Oil Prices Dip • IH Market News • 04/16/2024 11:19:33 AM
- Ericsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More News • IH Market News • 04/16/2024 11:18:19 AM
- Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% • Business Wire • 04/16/2024 10:25:00 AM
- Johnson & Johnson Reports Q1 2024 Results • Business Wire • 04/16/2024 10:20:00 AM
- U.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales Data • IH Market News • 04/15/2024 08:38:32 PM
- Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 04/08/2024 10:06:00 PM
- CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy • PR Newswire (US) • 04/06/2024 03:21:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc. • PR Newswire (US) • 04/05/2024 06:55:00 PM
- Apple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More Updates • IH Market News • 04/05/2024 11:38:57 AM
- Johnson & Johnson to Acquire Shockwave Medical • Business Wire • 04/05/2024 10:31:00 AM
- Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation • Business Wire • 04/04/2024 10:01:00 PM
- Johnson & Johnson to Participate in the BofA Securities Health Care Conference • Business Wire • 04/02/2024 08:30:00 PM
- Walgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest News • IH Market News • 03/28/2024 01:48:04 PM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge • GlobeNewswire Inc. • 03/12/2024 01:15:00 PM
- Johnson & Johnson to Host Investor Conference Call on First-Quarter Results • Business Wire • 03/11/2024 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:58:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:58:22 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM